AI in Drug Discovery Market by Drug Type (Small Molecule and Large Molecule) by Technology (Deep Learning, Machine Learning and Others) by Application (Target Identification and Validation, Drugs Design and Redesign, Preclinical Testing and Others), by Organization Size (Small and Medium Organizations and Large Organizations) by Therapeutic Area (Cardiovascular Disease, Metabolic Disease, Neurodegenerative Diseases, Dermatological Diseases, Infectious Diseases, Oncology and Others) by End Users (Pharmaceutical Companies, Research Centers and Laboratories, Clinicians and Drug Developers and Others); By Region (U.S., Canada, Mexico, Rest of North America, France, UK, Germany, Spain, Italy, Nordic Countries, Benelux Union, Rest of Europe, China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Rest of Asia Pacific, Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of MEA, Brazil, Argentina, Rest of Latin America) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2020 - 2028

Report ID :AMI-731 | Category : Healthcare & IT | Published Date : April, 3300 | Pages : 402 | Format :PDF

Industry Trends

Global AI in Drug Discovery market was valued at US$ 281 million in 2019 and is expected to reach US$ 1597.02 million by 2028, growing at a CAGR of 35.64% over the forecast period. AI-enabled solutions are emerging as a key instrument for transforming the process of investigating mechanisms of action for diseases and revolutionising the understanding of how drugs bind to targets, enhancing the overall drug discovery process. AI applications in drug development have already provided new candidate medicines through the mining of such data in some cases in months instead of years. AI technologies have the ability to kick-start the efficiency of the entire R&D process if implemented at the drug-discovery level. In order to incorporate AI solutions into conventional systems, biopharma companies need to build a comprehensive strategy.

AI decreases drug development timelines and increases the agility of the testing phase, which could speed up the discovery and preclinical stages by effectively applying revolutionary technologies. Due to issues of effectiveness and protection most drugs fail to make it to market. A ten percent increase in the accuracy of forecasts could save billions of dollars spent on drug production, considering the increasing cost of getting a drug to the market. These factors boost the demand for AI in drug discovery market. AI-enabled prediction instruments will increase the speed and accuracy of discovery and preclinical testing, open up new research lines and allow more competitive R&D strategies to improve the ability to diversify drug channels.

Although AI may have a role to play in biologics development, its use is primarily based on chemical, small molecule research applications so far. The healthcare sector is being constantly disrupted by tech giants. What distinguishes them is that these firms are already investing in AI for drug discovery, including many technology companies announcing collaborations with research institutions.

However, the adoption of AI has many legal problems majorly intellectual property is one of the most important. The introduction of AI into pharma and drug discovery processes presents many legal challenges, probably the main challenge is to get the correct and sufficiently large data sets commercially and adopt the right AI to train it in the right way. Moreover, AI is experiencing growth in the market for drug discovery in emerging regions in terms of its adoption rate due to the growth of pharmaceutical industries through partnership with other industries and the increasing need to minimise drug discovery and cost along with reduced time. In addition, the advancement of the biotechnology industry would generate new opportunities for business growth. Market growth is expected to be fuelled by the increase in the importance of AI in drug discovery and production and the increase in financing of R&D activities for the adoption of Artificial Intelligence in the drug discovery. Companies in the market are focussing on reducing the time of providing drugs for various diseases, AI helps in shortening the time for drug discovery process thus. AI has high demand in the drug discovery process for offering drugs for various infectious and incurable diseases. Market players are keen to reduce the cost of drug development. Deploying AI will aid the market players in doing so thus demand for AI in drug development will increase significantly over the years.

Drug Type Insights

In the drug type insights small molecule segment will show a potential growth in the market over the years. Majority of drugs that are being produced are chemically synthesized small molecules. The majority of drugs available in the market or are in development phase are being synthesized from small molecules. Small molecule has various advantages like stable shelf life, it is simple to manufacture, simple administration routes and low specificity. Drugs derived from small molecules are found safe and effective during the clinical trial phase. When tested on large group of people these drugs have efficient outcomes and these drugs are generally preferred by various pharmaceutical companies during clinical trial phase.

Technology Insights

Major Pharma companies are showing keen interest in AI driven solutions during drug discovery, machine learning solutions are increasingly adopted by various end users. Researchers looking for new antibiotics and antisense drugs are adopting machine learning algorithms. Machine learning algorithms aid in identifying hidden patterns and makes classifications during drug discovery. ML can also predict future outcomes thus this technology is increasingly getting adopted in various organizations.

Application Insights

AI in drug discovery has various applications, AI is being increasingly used for drugs design and redesign. The providers are engaged in delivering various AI models that could help the drug manufacturers in designing of new drugs. These AI based models are also aiding to gather and track data during the preclinical testing process.

Organization Size Insights

AI based solutions are increasingly getting adopted in the medium as well as large enterprises. The end users are relying on AI based solutions to predict future outcomes. As the cost of drug development is high companies are turning towards AI as it aids in various processes during development. Adoption of AI is high in large organization as compared to medium enterprises because large organizations are continuously engrossed in the making of new drugs in the market.

Therapeutic Area Insights

In the therapeutic area oncology segment dominates the market for AI in drug discover, as the number of people affected with cancer has risen the companies are engaged in adopting best possible solutions for treatment of cancers. AI plays a vital role in treatment of cancer, the platform aids in identifying genetic mutation and help the professionals in deriving a treatment plan.

End Users

The adoption of market offerings has been dependent on the overview of the drug manufacturers towards the overall drug development process. The adoption of AI in drug discovery by major pharmaceutical companies is on the rise and these companies are focussing on adopting this technology in order to reduce the cost of development of drug. The pharmaceutical companies face many challenges while launching a new drug in the market. One out of ten drugs are approved by the regulatory authorities, so in order to enhance the drug development process pharmaceutical companies are integrating AI based solutions in their existing infrastructure.

Regional Insights

The investments towards drug discovery have been important for the advancement in the healthcare sector. The initiatives from organizations in the public domain and private entities have been notable for the development of a wide range of drugs. The adoption of artificial intelligence has been observed to be majorly in developed countries and then in the developing countries. Regions such as North America are observed to be the major adopters for the offerings in the market. The increasing awareness among organizations in the region regarding the benefits of the market offerings in the drug development process along with the initiatives from the market participants for developing their offerings through feature improvements. The growing prevalence of numerous diseases is expected to aid the growth for adoption of market offerings in the region over the forecast period. The region of Asia Pacific is observed to be a notable part for the manufacturing of various drugs. In addition to this, drug manufacturers are now focusing towards expanding their research centres across various regions in order to enhance their potential for drug development. In addition to this, governing authorities across various countries are encouraging investments in their countries along with integration of newer technologies across various industry verticals. These efforts from drug manufacturers and governing authorities can be helpful for the growth of the market in the region over the near future.

AI in Drug Discovery Market Revenue & Forecast, (US$ Million), 2020 – 2028

Competitive Landscape

The report provides both, qualitative and quantitative research AI in Drug Discovery market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contacts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.

The major players operating in the market are Atomwise, Inc, BenevolentAI Ltd, BERG LLC, BIOAGE, Cloud Pharmaceuticals, Inc., DEEP GENOMICS, Envisagenics, EVAXION BIOTECH A/S, Exscientia, Google LLC, HACARUS INC, IBM Corp, Insilico Medicine, Microsoft, NuMedii, Inc., OWKIN, INC., twoXAR, Incorporated, VERGE genomics, XtalPi Inc., Cyclica and other market participants.

AI in Drug Discovery Market:

By Drug Type
- Small Molecule
- Large Molecule
By Technology
- Deep Learning
- Machine Learning
- Others
By Application
- Target Identification and Validation
- Drugs Design and Redesign
- Preclinical Testing
- Others
By Organization Size
- Small and Medium Organizations
- Large Organizations
By Therapeutic Area
- Cardiovascular Disease
- Metabolic Disease
- Neurodegenerative Diseases
- Dermatological Diseases
- Infectious Diseases
- Oncology
- Others

Table of Contents

1. Market Scope

1.1. Market Segmentation

1.2. Years Considered

1.2.1. Historic Years: 2015 - 2018

1.2.2. Base Year: 2019

1.2.3. Forecast Years: 2020 – 2028

2. Key Target Audiences

3. Research Methodology

3.1. Primary Research

3.1.1. Research Questionnaire

3.1.2. Global Percentage Breakdown

3.1.3. Primary Interviews: Key Opinion Leaders (KOLs)

3.2. Secondary Research

3.2.1. Paid Databases

3.2.2. Secondary Sources

3.3. Market Size Estimates

3.3.1. Top-Down Approach

3.3.2. Bottom-Up Approach

3.4. Data Triangulation Methodology

3.5. Research Assumptions

4. Recommendations and Insights from AMI’s Perspective**

5. Holistic Overview of AI in Drug Discovery Market

6. Market Synopsis: AI in Drug Discovery Market

7. AI in Drug Discovery Market Analysis: Qualitative Perspective

7.1. Introduction

7.1.1. Product Definition

7.1.2. Industry Development

7.2. Market Dynamics

7.2.1. Drivers

7.2.2. Restraints

7.2.3. Opportunities

7.3. Trends in AI in Drug Discovery Market

7.4. Market Determinants Radar Chart

7.5. Macro-Economic and Micro-Economic Indicators: AI in Drug Discovery Market

7.6. Porter’s Five Force Analysis

7.7. Impact of Covid-19 on AI in Drug Discovery Market

8. Global AI in Drug Discovery Market Analysis and Forecasts, 2020 – 2028

8.1. Overview

8.1.1. Global AI in Drug Discovery Market Revenue (US$ Mn)

8.2. Global AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Drug Type

8.2.1. Small Molecule

8.2.1.1. Definition

8.2.1.2. Market Estimation and Penetration, 2015 – 2019

8.2.1.3. Market Forecast, 2020 – 2028

8.2.1.4. Compound Annual Growth Rate (CAGR)

8.2.1.5. Regional Bifurcation

8.2.1.5.1. North America

8.2.1.5.1.1. Market Estimation, 2015 – 2019

8.2.1.5.1.2. Market Forecast, 2020 – 2028

8.2.1.5.2. Europe

8.2.1.5.2.1. Market Estimation, 2015 – 2019

8.2.1.5.2.2. Market Forecast, 2020 – 2028

8.2.1.5.3. Asia Pacific

8.2.1.5.3.1. Market Estimation, 2015 – 2019

8.2.1.5.3.2. Market Forecast, 2020 – 2028

8.2.1.5.4. Middle East and Africa

8.2.1.5.4.1. Market Estimation, 2015 – 2019

8.2.1.5.4.2. Market Forecast, 2020 – 2028

8.2.1.5.5. Latin America

8.2.1.5.5.1. Market Estimation, 2015 – 2019

8.2.1.5.5.2. Market Forecast, 2020 – 2028

8.2.2. Large Molecule

8.2.2.1. Definition

8.2.2.2. Market Estimation and Penetration, 2015 – 2019

8.2.2.3. Market Forecast, 2020 – 2028

8.2.2.4. Compound Annual Growth Rate (CAGR)

8.2.2.5. Regional Bifurcation

8.2.2.5.1. North America

8.2.2.5.1.1. Market Estimation, 2015 – 2019

8.2.2.5.1.2. Market Forecast, 2020 – 2028

8.2.2.5.2. Europe

8.2.2.5.2.1. Market Estimation, 2015 – 2019

8.2.2.5.2.2. Market Forecast, 2020 – 2028

8.2.2.5.3. Asia Pacific

8.2.2.5.3.1. Market Estimation, 2015 – 2019

8.2.2.5.3.2. Market Forecast, 2020 – 2028

8.2.2.5.4. Middle East and Africa

8.2.2.5.4.1. Market Estimation, 2015 – 2019

8.2.2.5.4.2. Market Forecast, 2020 – 2028

8.2.2.5.5. Latin America

8.2.2.5.5.1. Market Estimation, 2015 – 2019

8.2.2.5.5.2. Market Forecast, 2020 – 2028

8.3. Key Segment for Channeling Investments

8.3.1. By Drug Type

9. Global AI in Drug Discovery Market Analysis and Forecasts, 2020 – 2028

9.1. Overview

9.2. Global AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Technology

9.2.1. Deep Learning

9.2.1.1. Definition

9.2.1.2. Market Estimation and Penetration, 2015 – 2019

9.2.1.3. Market Forecast, 2020 – 2028

9.2.1.4. Compound Annual Growth Rate (CAGR)

9.2.1.5. Regional Bifurcation

9.2.1.5.1. North America

9.2.1.5.1.1. Market Estimation, 2015 – 2019

9.2.1.5.1.2. Market Forecast, 2020 – 2028

9.2.1.5.2. Europe

9.2.1.5.2.1. Market Estimation, 2015 – 2019

9.2.1.5.2.2. Market Forecast, 2020 – 2028

9.2.1.5.3. Asia Pacific

9.2.1.5.3.1. Market Estimation, 2015 – 2019

9.2.1.5.3.2. Market Forecast, 2020 – 2028

9.2.1.5.4. Middle East and Africa

9.2.1.5.4.1. Market Estimation, 2015 – 2019

9.2.1.5.4.2. Market Forecast, 2020 – 2028

9.2.1.5.5. Latin America

9.2.1.5.5.1. Market Estimation, 2015 – 2019

9.2.1.5.5.2. Market Forecast, 2020 – 2028

9.2.2. Machine Learning

9.2.2.1. Definition

9.2.2.2. Market Estimation and Penetration, 2015 – 2019

9.2.2.3. Market Forecast, 2020 – 2028

9.2.2.4. Compound Annual Growth Rate (CAGR)

9.2.2.5. Regional Bifurcation

9.2.2.5.1. North America

9.2.2.5.1.1. Market Estimation, 2015 – 2019

9.2.2.5.1.2. Market Forecast, 2020 – 2028

9.2.2.5.2. Europe

9.2.2.5.2.1. Market Estimation, 2015 – 2019

9.2.2.5.2.2. Market Forecast, 2020 – 2028

9.2.2.5.3. Asia Pacific

9.2.2.5.3.1. Market Estimation, 2015 – 2019

9.2.2.5.3.2. Market Forecast, 2020 – 2028

9.2.2.5.4. Middle East and Africa

9.2.2.5.4.1. Market Estimation, 2015 – 2019

9.2.2.5.4.2. Market Forecast, 2020 – 2028

9.2.2.5.5. Latin America

9.2.2.5.5.1. Market Estimation, 2015 – 2019

9.2.2.5.5.2. Market Forecast, 2020 – 2028

9.2.3. Others

9.2.3.1. Definition

9.2.3.2. Market Estimation and Penetration, 2015 – 2019

9.2.3.3. Market Forecast, 2020 – 2028

9.2.3.4. Compound Annual Growth Rate (CAGR)

9.2.3.5. Regional Bifurcation

9.2.3.5.1. North America

9.2.3.5.1.1. Market Estimation, 2015 – 2019

9.2.3.5.1.2. Market Forecast, 2020 – 2028

9.2.3.5.2. Europe

9.2.3.5.2.1. Market Estimation, 2015 – 2019

9.2.3.5.2.2. Market Forecast, 2020 – 2028

9.2.3.5.3. Asia Pacific

9.2.3.5.3.1. Market Estimation, 2015 – 2019

9.2.3.5.3.2. Market Forecast, 2020 – 2028

9.2.3.5.4. Middle East and Africa

9.2.3.5.4.1. Market Estimation, 2015 – 2019

9.2.3.5.4.2. Market Forecast, 2020 – 2028

9.2.3.5.5. Latin America

9.2.3.5.5.1. Market Estimation, 2015 – 2019

9.2.3.5.5.2. Market Forecast, 2020 – 2028

9.3. Key Segment for Channeling Investments

9.3.1. By Technology

10. Global AI in Drug Discovery Market Analysis and Forecasts, 2020 – 2028

10.1. Overview

10.2. Global AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Application

10.2.1. Target Identification and Validation

10.2.1.1. Definition

10.2.1.2. Market Estimation and Penetration, 2015 – 2019

10.2.1.3. Market Forecast, 2020 – 2028

10.2.1.4. Compound Annual Growth Rate (CAGR)

10.2.1.5. Regional Bifurcation

10.2.1.5.1. North America

10.2.1.5.1.1. Market Estimation, 2015 – 2019

10.2.1.5.1.2. Market Forecast, 2020 – 2028

10.2.1.5.2. Europe

10.2.1.5.2.1. Market Estimation, 2015 – 2019

10.2.1.5.2.2. Market Forecast, 2020 – 2028

10.2.1.5.3. Asia Pacific

10.2.1.5.3.1. Market Estimation, 2015 – 2019

10.2.1.5.3.2. Market Forecast, 2020 – 2028

10.2.1.5.4. Middle East and Africa

10.2.1.5.4.1. Market Estimation, 2015 – 2019

10.2.1.5.4.2. Market Forecast, 2020 – 2028

10.2.1.5.5. Latin America

10.2.1.5.5.1. Market Estimation, 2015 – 2019

10.2.1.5.5.2. Market Forecast, 2020 – 2028

10.2.2. Drugs Design and Redesign

10.2.2.1. Definition

10.2.2.2. Market Estimation and Penetration, 2015 – 2019

10.2.2.3. Market Forecast, 2020 – 2028

10.2.2.4. Compound Annual Growth Rate (CAGR)

10.2.2.5. Regional Bifurcation

10.2.2.5.1. North America

10.2.2.5.1.1. Market Estimation, 2015 – 2019

10.2.2.5.1.2. Market Forecast, 2020 – 2028

10.2.2.5.2. Europe

10.2.2.5.2.1. Market Estimation, 2015 – 2019

10.2.2.5.2.2. Market Forecast, 2020 – 2028

10.2.2.5.3. Asia Pacific

10.2.2.5.3.1. Market Estimation, 2015 – 2019

10.2.2.5.3.2. Market Forecast, 2020 – 2028

10.2.2.5.4. Middle East and Africa

10.2.2.5.4.1. Market Estimation, 2015 – 2019

10.2.2.5.4.2. Market Forecast, 2020 – 2028

10.2.2.5.5. Latin America

10.2.2.5.5.1. Market Estimation, 2015 – 2019

10.2.2.5.5.2. Market Forecast, 2020 – 2028

10.2.3. Preclinical Testing

10.2.3.1. Definition

10.2.3.2. Market Estimation and Penetration, 2015 – 2019

10.2.3.3. Market Forecast, 2020 – 2028

10.2.3.4. Compound Annual Growth Rate (CAGR)

10.2.3.5. Regional Bifurcation

10.2.3.5.1. North America

10.2.3.5.1.1. Market Estimation, 2015 – 2019

10.2.3.5.1.2. Market Forecast, 2020 – 2028

10.2.3.5.2. Europe

10.2.3.5.2.1. Market Estimation, 2015 – 2019

10.2.3.5.2.2. Market Forecast, 2020 – 2028

10.2.3.5.3. Asia Pacific

10.2.3.5.3.1. Market Estimation, 2015 – 2019

10.2.3.5.3.2. Market Forecast, 2020 – 2028

10.2.3.5.4. Middle East and Africa

10.2.3.5.4.1. Market Estimation, 2015 – 2019

10.2.3.5.4.2. Market Forecast, 2020 – 2028

10.2.3.5.5. Latin America

10.2.3.5.5.1. Market Estimation, 2015 – 2019

10.2.3.5.5.2. Market Forecast, 2020 – 2028

10.2.4. Others

10.2.4.1. Definition

10.2.4.2. Market Estimation and Penetration, 2015 – 2019

10.2.4.3. Market Forecast, 2020 – 2028

10.2.4.4. Compound Annual Growth Rate (CAGR)

10.2.4.5. Regional Bifurcation

10.2.4.5.1. North America

10.2.4.5.1.1. Market Estimation, 2015 – 2019

10.2.4.5.1.2. Market Forecast, 2020 – 2028

10.2.4.5.2. Europe

10.2.4.5.2.1. Market Estimation, 2015 – 2019

10.2.4.5.2.2. Market Forecast, 2020 – 2028

10.2.4.5.3. Asia Pacific

10.2.4.5.3.1. Market Estimation, 2015 – 2019

10.2.4.5.3.2. Market Forecast, 2020 – 2028

10.2.4.5.4. Middle East and Africa

10.2.4.5.4.1. Market Estimation, 2015 – 2019

10.2.4.5.4.2. Market Forecast, 2020 – 2028

10.2.4.5.5. Latin America

10.2.4.5.5.1. Market Estimation, 2015 – 2019

10.2.4.5.5.2. Market Forecast, 2020 – 2028

10.3. Key Segment for Channeling Investments

10.3.1. By Application

11. Global AI in Drug Discovery Market Analysis and Forecasts, 2020 – 2028

11.1. Overview

11.2. Global AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Organization Size

11.2.1. Small and Medium Organizations

11.2.1.1. Definition

11.2.1.2. Market Estimation and Penetration, 2015 – 2019

11.2.1.3. Market Forecast, 2020 – 2028

11.2.1.4. Compound Annual Growth Rate (CAGR)

11.2.1.5. Regional Bifurcation

11.2.1.5.1. North America

11.2.1.5.1.1. Market Estimation, 2015 – 2019

11.2.1.5.1.2. Market Forecast, 2020 – 2028

11.2.1.5.2. Europe

11.2.1.5.2.1. Market Estimation, 2015 – 2019

11.2.1.5.2.2. Market Forecast, 2020 – 2028

11.2.1.5.3. Asia Pacific

11.2.1.5.3.1. Market Estimation, 2015 – 2019

11.2.1.5.3.2. Market Forecast, 2020 – 2028

11.2.1.5.4. Middle East and Africa

11.2.1.5.4.1. Market Estimation, 2015 – 2019

11.2.1.5.4.2. Market Forecast, 2020 – 2028

11.2.1.5.5. Latin America

11.2.1.5.5.1. Market Estimation, 2015 – 2019

11.2.1.5.5.2. Market Forecast, 2020 – 2028

11.2.2. Large Organizations

11.2.2.1. Definition

11.2.2.2. Market Estimation and Penetration, 2015 – 2019

11.2.2.3. Market Forecast, 2020 – 2028

11.2.2.4. Compound Annual Growth Rate (CAGR)

11.2.2.5. Regional Bifurcation

11.2.2.5.1. North America

11.2.2.5.1.1. Market Estimation, 2015 – 2019

11.2.2.5.1.2. Market Forecast, 2020 – 2028

11.2.2.5.2. Europe

11.2.2.5.2.1. Market Estimation, 2015 – 2019

11.2.2.5.2.2. Market Forecast, 2020 – 2028

11.2.2.5.3. Asia Pacific

11.2.2.5.3.1. Market Estimation, 2015 – 2019

11.2.2.5.3.2. Market Forecast, 2020 – 2028

11.2.2.5.4. Middle East and Africa

11.2.2.5.4.1. Market Estimation, 2015 – 2019

11.2.2.5.4.2. Market Forecast, 2020 – 2028

11.2.2.5.5. Latin America

11.2.2.5.5.1. Market Estimation, 2015 – 2019

11.2.2.5.5.2. Market Forecast, 2020 – 2028

11.3. Key Segment for Channeling Investments

11.3.1. By Organization Size

12. Global AI in Drug Discovery Market Analysis and Forecasts, 2020 – 2028

12.1. Overview

12.2. Global AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area

12.2.1. Cardiovascular Disease

12.2.1.1. Definition

12.2.1.2. Market Estimation and Penetration, 2015 – 2019

12.2.1.3. Market Forecast, 2020 – 2028

12.2.1.4. Compound Annual Growth Rate (CAGR)

12.2.1.5. Regional Bifurcation

12.2.1.5.1. North America

12.2.1.5.1.1. Market Estimation, 2015 – 2019

12.2.1.5.1.2. Market Forecast, 2020 – 2028

12.2.1.5.2. Europe

12.2.1.5.2.1. Market Estimation, 2015 – 2019

12.2.1.5.2.2. Market Forecast, 2020 – 2028

12.2.1.5.3. Asia Pacific

12.2.1.5.3.1. Market Estimation, 2015 – 2019

12.2.1.5.3.2. Market Forecast, 2020 – 2028

12.2.1.5.4. Middle East and Africa

12.2.1.5.4.1. Market Estimation, 2015 – 2019

12.2.1.5.4.2. Market Forecast, 2020 – 2028

12.2.1.5.5. Latin America

12.2.1.5.5.1. Market Estimation, 2015 – 2019

12.2.1.5.5.2. Market Forecast, 2020 – 2028

12.2.2. Metabolic Disease

12.2.2.1. Definition

12.2.2.2. Market Estimation and Penetration, 2015 – 2019

12.2.2.3. Market Forecast, 2020 – 2028

12.2.2.4. Compound Annual Growth Rate (CAGR)

12.2.2.5. Regional Bifurcation

12.2.2.5.1. North America

12.2.2.5.1.1. Market Estimation, 2015 – 2019

12.2.2.5.1.2. Market Forecast, 2020 – 2028

12.2.2.5.2. Europe

12.2.2.5.2.1. Market Estimation, 2015 – 2019

12.2.2.5.2.2. Market Forecast, 2020 – 2028

12.2.2.5.3. Asia Pacific

12.2.2.5.3.1. Market Estimation, 2015 – 2019

12.2.2.5.3.2. Market Forecast, 2020 – 2028

12.2.2.5.4. Middle East and Africa

12.2.2.5.4.1. Market Estimation, 2015 – 2019

12.2.2.5.4.2. Market Forecast, 2020 – 2028

12.2.2.5.5. Latin America

12.2.2.5.5.1. Market Estimation, 2015 – 2019

12.2.2.5.5.2. Market Forecast, 2020 – 2028

12.2.3. Neurodegenerative Diseases

12.2.3.1. Definition

12.2.3.2. Market Estimation and Penetration, 2015 – 2019

12.2.3.3. Market Forecast, 2020 – 2028

12.2.3.4. Compound Annual Growth Rate (CAGR)

12.2.3.5. Regional Bifurcation

12.2.3.5.1. North America

12.2.3.5.1.1. Market Estimation, 2015 – 2019

12.2.3.5.1.2. Market Forecast, 2020 – 2028

12.2.3.5.2. Europe

12.2.3.5.2.1. Market Estimation, 2015 – 2019

12.2.3.5.2.2. Market Forecast, 2020 – 2028

12.2.3.5.3. Asia Pacific

12.2.3.5.3.1. Market Estimation, 2015 – 2019

12.2.3.5.3.2. Market Forecast, 2020 – 2028

12.2.3.5.4. Middle East and Africa

12.2.3.5.4.1. Market Estimation, 2015 – 2019

12.2.3.5.4.2. Market Forecast, 2020 – 2028

12.2.3.5.5. Latin America

12.2.3.5.5.1. Market Estimation, 2015 – 2019

12.2.3.5.5.2. Market Forecast, 2020 – 2028

12.2.4. Dermatological Diseases

12.2.4.1. Definition

12.2.4.2. Market Estimation and Penetration, 2015 – 2019

12.2.4.3. Market Forecast, 2020 – 2028

12.2.4.4. Compound Annual Growth Rate (CAGR)

12.2.4.5. Regional Bifurcation

12.2.4.5.1. North America

12.2.4.5.1.1. Market Estimation, 2015 – 2019

12.2.4.5.1.2. Market Forecast, 2020 – 2028

12.2.4.5.2. Europe

12.2.4.5.2.1. Market Estimation, 2015 – 2019

12.2.4.5.2.2. Market Forecast, 2020 – 2028

12.2.4.5.3. Asia Pacific

12.2.4.5.3.1. Market Estimation, 2015 – 2019

12.2.4.5.3.2. Market Forecast, 2020 – 2028

12.2.4.5.4. Middle East and Africa

12.2.4.5.4.1. Market Estimation, 2015 – 2019

12.2.4.5.4.2. Market Forecast, 2020 – 2028

12.2.4.5.5. Latin America

12.2.4.5.5.1. Market Estimation, 2015 – 2019

12.2.4.5.5.2. Market Forecast, 2020 – 2028

12.2.5. Infectious Diseases

12.2.5.1. Definition

12.2.5.2. Market Estimation and Penetration, 2015 – 2019

12.2.5.3. Market Forecast, 2020 – 2028

12.2.5.4. Compound Annual Growth Rate (CAGR)

12.2.5.5. Regional Bifurcation

12.2.5.5.1. North America

12.2.5.5.1.1. Market Estimation, 2015 – 2019

12.2.5.5.1.2. Market Forecast, 2020 – 2028

12.2.5.5.2. Europe

12.2.5.5.2.1. Market Estimation, 2015 – 2019

12.2.5.5.2.2. Market Forecast, 2020 – 2028

12.2.5.5.3. Asia Pacific

12.2.5.5.3.1. Market Estimation, 2015 – 2019

12.2.5.5.3.2. Market Forecast, 2020 – 2028

12.2.5.5.4. Middle East and Africa

12.2.5.5.4.1. Market Estimation, 2015 – 2019

12.2.5.5.4.2. Market Forecast, 2020 – 2028

12.2.5.5.5. Latin America

12.2.5.5.5.1. Market Estimation, 2015 – 2019

12.2.5.5.5.2. Market Forecast, 2020 – 2028

12.2.6. Oncology

12.2.6.1. Definition

12.2.6.2. Market Estimation and Penetration, 2015 – 2019

12.2.6.3. Market Forecast, 2020 – 2028

12.2.6.4. Compound Annual Growth Rate (CAGR)

12.2.6.5. Regional Bifurcation

12.2.6.5.1. North America

12.2.6.5.1.1. Market Estimation, 2015 – 2019

12.2.6.5.1.2. Market Forecast, 2020 – 2028

12.2.6.5.2. Europe

12.2.6.5.2.1. Market Estimation, 2015 – 2019

12.2.6.5.2.2. Market Forecast, 2020 – 2028

12.2.6.5.3. Asia Pacific

12.2.6.5.3.1. Market Estimation, 2015 – 2019

12.2.6.5.3.2. Market Forecast, 2020 – 2028

12.2.6.5.4. Middle East and Africa

12.2.6.5.4.1. Market Estimation, 2015 – 2019

12.2.6.5.4.2. Market Forecast, 2020 – 2028

12.2.6.5.5. Latin America

12.2.6.5.5.1. Market Estimation, 2015 – 2019

12.2.6.5.5.2. Market Forecast, 2020 – 2028

12.2.7. Others

12.2.7.1. Definition

12.2.7.2. Market Estimation and Penetration, 2015 – 2019

12.2.7.3. Market Forecast, 2020 – 2028

12.2.7.4. Compound Annual Growth Rate (CAGR)

12.2.7.5. Regional Bifurcation

12.2.7.5.1. North America

12.2.7.5.1.1. Market Estimation, 2015 – 2019

12.2.7.5.1.2. Market Forecast, 2020 – 2028

12.2.7.5.2. Europe

12.2.7.5.2.1. Market Estimation, 2015 – 2019

12.2.7.5.2.2. Market Forecast, 2020 – 2028

12.2.7.5.3. Asia Pacific

12.2.7.5.3.1. Market Estimation, 2015 – 2019

12.2.7.5.3.2. Market Forecast, 2020 – 2028

12.2.7.5.4. Middle East and Africa

12.2.7.5.4.1. Market Estimation, 2015 – 2019

12.2.7.5.4.2. Market Forecast, 2020 – 2028

12.2.7.5.5. Latin America

12.2.7.5.5.1. Market Estimation, 2015 – 2019

12.2.7.5.5.2. Market Forecast, 2020 – 2028

12.3. Key Segment for Channeling Investments

12.3.1. By Therapeutic Area

13. Global AI in Drug Discovery Market Analysis and Forecasts, 2020 – 2028

13.1. Overview

13.2. Global AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By End Users

13.2.1. Pharmaceutical Companies

13.2.1.1. Definition

13.2.1.2. Market Estimation and Penetration, 2015 – 2019

13.2.1.3. Market Forecast, 2020 – 2028

13.2.1.4. Compound Annual Growth Rate (CAGR)

13.2.1.5. Regional Bifurcation

13.2.1.5.1. North America

13.2.1.5.1.1. Market Estimation, 2015 – 2019

13.2.1.5.1.2. Market Forecast, 2020 – 2028

13.2.1.5.2. Europe

13.2.1.5.2.1. Market Estimation, 2015 – 2019

13.2.1.5.2.2. Market Forecast, 2020 – 2028

13.2.1.5.3. Asia Pacific

13.2.1.5.3.1. Market Estimation, 2015 – 2019

13.2.1.5.3.2. Market Forecast, 2020 – 2028

13.2.1.5.4. Middle East and Africa

13.2.1.5.4.1. Market Estimation, 2015 – 2019

13.2.1.5.4.2. Market Forecast, 2020 – 2028

13.2.1.5.5. Latin America

13.2.1.5.5.1. Market Estimation, 2015 – 2019

13.2.1.5.5.2. Market Forecast, 2020 – 2028

13.2.2. Research Centers and Laboratories

13.2.2.1. Definition

13.2.2.2. Market Estimation and Penetration, 2015 – 2019

13.2.2.3. Market Forecast, 2020 – 2028

13.2.2.4. Compound Annual Growth Rate (CAGR)

13.2.2.5. Regional Bifurcation

13.2.2.5.1. North America

13.2.2.5.1.1. Market Estimation, 2015 – 2019

13.2.2.5.1.2. Market Forecast, 2020 – 2028

13.2.2.5.2. Europe

13.2.2.5.2.1. Market Estimation, 2015 – 2019

13.2.2.5.2.2. Market Forecast, 2020 – 2028

13.2.2.5.3. Asia Pacific

13.2.2.5.3.1. Market Estimation, 2015 – 2019

13.2.2.5.3.2. Market Forecast, 2020 – 2028

13.2.2.5.4. Middle East and Africa

13.2.2.5.4.1. Market Estimation, 2015 – 2019

13.2.2.5.4.2. Market Forecast, 2020 – 2028

13.2.2.5.5. Latin America

13.2.2.5.5.1. Market Estimation, 2015 – 2019

13.2.2.5.5.2. Market Forecast, 2020 – 2028

13.2.3. Clinicians and Drug Developers

13.2.3.1. Definition

13.2.3.2. Market Estimation and Penetration, 2015 – 2019

13.2.3.3. Market Forecast, 2020 – 2028

13.2.3.4. Compound Annual Growth Rate (CAGR)

13.2.3.5. Regional Bifurcation

13.2.3.5.1. North America

13.2.3.5.1.1. Market Estimation, 2015 – 2019

13.2.3.5.1.2. Market Forecast, 2020 – 2028

13.2.3.5.2. Europe

13.2.3.5.2.1. Market Estimation, 2015 – 2019

13.2.3.5.2.2. Market Forecast, 2020 – 2028

13.2.3.5.3. Asia Pacific

13.2.3.5.3.1. Market Estimation, 2015 – 2019

13.2.3.5.3.2. Market Forecast, 2020 – 2028

13.2.3.5.4. Middle East and Africa

13.2.3.5.4.1. Market Estimation, 2015 – 2019

13.2.3.5.4.2. Market Forecast, 2020 – 2028

13.2.3.5.5. Latin America

13.2.3.5.5.1. Market Estimation, 2015 – 2019

13.2.3.5.5.2. Market Forecast, 2020 – 2028

13.2.4. Others

13.2.4.1. Definition

13.2.4.2. Market Estimation and Penetration, 2015 – 2019

13.2.4.3. Market Forecast, 2020 – 2028

13.2.4.4. Compound Annual Growth Rate (CAGR)

13.2.4.5. Regional Bifurcation

13.2.4.5.1. North America

13.2.4.5.1.1. Market Estimation, 2015 – 2019

13.2.4.5.1.2. Market Forecast, 2020 – 2028

13.2.4.5.2. Europe

13.2.4.5.2.1. Market Estimation, 2015 – 2019

13.2.4.5.2.2. Market Forecast, 2020 – 2028

13.2.4.5.3. Asia Pacific

13.2.4.5.3.1. Market Estimation, 2015 – 2019

13.2.4.5.3.2. Market Forecast, 2020 – 2028

13.2.4.5.4. Middle East and Africa

13.2.4.5.4.1. Market Estimation, 2015 – 2019

13.2.4.5.4.2. Market Forecast, 2020 – 2028

13.2.4.5.5. Latin America

13.2.4.5.5.1. Market Estimation, 2015 – 2019

13.2.4.5.5.2. Market Forecast, 2020 – 2028

13.3. Key Segment for Channeling Investments

13.3.1. By End Users

14. North America AI in Drug Discovery Market Analysis and Forecasts, 2020 - 2028

14.1. Overview

14.1.1. North America AI in Drug Discovery Market Revenue (US$ Mn)

14.2. North America AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Drug Type

14.2.1. Small Molecule

14.2.2. Large Molecule

14.3. North America AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Technology

14.3.1. Deep Learning

14.3.2. Machine Learning

14.3.3. Others

14.4. North America AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Application

14.4.1. Target Identification and Validation

14.4.2. Drugs Design and Redesign

14.4.3. Preclinical Testing

14.4.4. Others

14.5. North America AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Organization Size

14.5.1. Small and Medium Organizations

14.5.2. Large Organizations

14.6. North America AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area

14.6.1. Cardiovascular Disease

14.6.2. Metabolic Disease

14.6.3. Neurodegenerative Diseases

14.6.4. Dermatological Diseases

14.6.5. Infectious Diseases

14.6.6. Oncology

14.6.7. Others

14.7. North America AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By End Users

14.7.1. Pharmaceutical Companies

14.7.2. Research Centers and Laboratories

14.7.3. Clinicians and Drug Developers

14.7.4. Others

14.8. North America AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Country

14.8.1. U.S

14.8.1.1. U.S AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Drug Type

14.8.1.1.1. Small Molecule

14.8.1.1.2. Large Molecule

14.8.1.2. U.S AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Technology

14.8.1.2.1. Deep Learning

14.8.1.2.2. Machine Learning

14.8.1.2.3. Others

14.8.1.3. U.S AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Application

14.8.1.3.1. Target Identification and Validation

14.8.1.3.2. Drugs Design and Redesign

14.8.1.3.3. Preclinical Testing

14.8.1.3.4. Others

14.8.1.4. U.S AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Organization Size

14.8.1.4.1. Small and Medium Organizations

14.8.1.4.2. Large Organizations

14.8.1.5. U.S AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area

14.8.1.5.1. Cardiovascular Disease

14.8.1.5.2. Metabolic Disease

14.8.1.5.3. Neurodegenerative Diseases

14.8.1.5.4. Dermatological Diseases

14.8.1.5.5. Infectious Diseases

14.8.1.5.6. Oncology

14.8.1.5.7. Others

14.8.1.6. U.S AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By End Users

14.8.1.6.1. Pharmaceutical Companies

14.8.1.6.2. Research Centers and Laboratories

14.8.1.6.3. Clinicians and Drug Developers

14.8.1.6.4. Others

14.8.2. Canada

14.8.2.1. Canada AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Drug Type

14.8.2.1.1. Small Molecule

14.8.2.1.2. Large Molecule

14.8.2.2. Canada AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Technology

14.8.2.2.1. Deep Learning

14.8.2.2.2. Machine Learning

14.8.2.2.3. Others

14.8.2.3. Canada AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Application

14.8.2.3.1. Target Identification and Validation

14.8.2.3.2. Drugs Design and Redesign

14.8.2.3.3. Preclinical Testing

14.8.2.3.4. Others

14.8.2.4. Canada AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Organization Size

14.8.2.4.1. Small and Medium Organizations

14.8.2.4.2. Large Organizations

14.8.2.5. Canada AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area

14.8.2.5.1. Cardiovascular Disease

14.8.2.5.2. Metabolic Disease

14.8.2.5.3. Neurodegenerative Diseases

14.8.2.5.4. Dermatological Diseases

14.8.2.5.5. Infectious Diseases

14.8.2.5.6. Oncology

14.8.2.5.7. Others

14.8.2.6. Canada AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By End Users

14.8.2.6.1. Pharmaceutical Companies

14.8.2.6.2. Research Centers and Laboratories

14.8.2.6.3. Clinicians and Drug Developers

14.8.2.6.4. Others

14.8.3. Mexico

14.8.3.1. Mexico AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Drug Type

14.8.3.1.1. Small Molecule

14.8.3.1.2. Large Molecule

14.8.3.2. Mexico AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Technology

14.8.3.2.1. Deep Learning

14.8.3.2.2. Machine Learning

14.8.3.2.3. Others

14.8.3.3. Mexico AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Application

14.8.3.3.1. Target Identification and Validation

14.8.3.3.2. Drugs Design and Redesign

14.8.3.3.3. Preclinical Testing

14.8.3.3.4. Others

14.8.3.4. Mexico AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Organization Size

14.8.3.4.1. Small and Medium Organizations

14.8.3.4.2. Large Organizations

14.8.3.5. Mexico AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area

14.8.3.5.1. Cardiovascular Disease

14.8.3.5.2. Metabolic Disease

14.8.3.5.3. Neurodegenerative Diseases

14.8.3.5.4. Dermatological Diseases

14.8.3.5.5. Infectious Diseases

14.8.3.5.6. Oncology

14.8.3.5.7. Others

14.8.3.6. Mexico AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By End Users

14.8.3.6.1. Pharmaceutical Companies

14.8.3.6.2. Research Centers and Laboratories

14.8.3.6.3. Clinicians and Drug Developers

14.8.3.6.4. Others

14.8.4. Rest of North America

14.8.4.1. Rest of North America AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Drug Type

14.8.4.1.1. Small Molecule

14.8.4.1.2. Large Molecule

14.8.4.2. Rest of North America AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Technology

14.8.4.2.1. Deep Learning

14.8.4.2.2. Machine Learning

14.8.4.2.3. Others

14.8.4.3. Rest of North America AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Application

14.8.4.3.1. Target Identification and Validation

14.8.4.3.2. Drugs Design and Redesign

14.8.4.3.3. Preclinical Testing

14.8.4.3.4. Others

14.8.4.4. Rest of North America AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Organization Size

14.8.4.4.1. Small and Medium Organizations

14.8.4.4.2. Large Organizations

14.8.4.5. Rest of North America AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area

14.8.4.5.1. Cardiovascular Disease

14.8.4.5.2. Metabolic Disease

14.8.4.5.3. Neurodegenerative Diseases

14.8.4.5.4. Dermatological Diseases

14.8.4.5.5. Infectious Diseases

14.8.4.5.6. Oncology

14.8.4.5.7. Others

14.8.4.6. Rest of North America AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By End Users

14.8.4.6.1. Pharmaceutical Companies

14.8.4.6.2. Research Centers and Laboratories

14.8.4.6.3. Clinicians and Drug Developers

14.8.4.6.4. Others

14.9. Key Segment for Channeling Investments

14.9.1. By Country

14.9.2. By Drug Type

14.9.3. By Technology

14.9.4. By Application

14.9.5. By Organization Size

14.9.6. By Therapeutic Area

14.9.7. By End Users

15. Europe AI in Drug Discovery Market Analysis and Forecasts, 2020 - 2028

15.1. Overview

15.1.1. Europe AI in Drug Discovery Market Revenue (US$ Mn)

15.2. Europe AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Drug Type

15.2.1. Small Molecule

15.2.2. Large Molecule

15.3. Europe AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Technology

15.3.1. Deep Learning

15.3.2. Machine Learning

15.3.3. Others

15.4. Europe AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Application

15.4.1. Target Identification and Validation

15.4.2. Drugs Design and Redesign

15.4.3. Preclinical Testing

15.4.4. Others

15.5. Europe AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Organization Size

15.5.1. Small and Medium Organizations

15.5.2. Large Organizations

15.6. Europe AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area

15.6.1. Cardiovascular Disease

15.6.2. Metabolic Disease

15.6.3. Neurodegenerative Diseases

15.6.4. Dermatological Diseases

15.6.5. Infectious Diseases

15.6.6. Oncology

15.6.7. Others

15.7. Europe AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By End Users

15.7.1. Pharmaceutical Companies

15.7.2. Research Centers and Laboratories

15.7.3. Clinicians and Drug Developers

15.7.4. Others

15.8. Europe AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Country

15.8.1. France

15.8.1.1. France AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Drug Type

15.8.1.1.1. Small Molecule

15.8.1.1.2. Large Molecule

15.8.1.2. France AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Technology

15.8.1.2.1. Deep Learning

15.8.1.2.2. Machine Learning

15.8.1.2.3. Others

15.8.1.3. France AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Application

15.8.1.3.1. Target Identification and Validation

15.8.1.3.2. Drugs Design and Redesign

15.8.1.3.3. Preclinical Testing

15.8.1.3.4. Others

15.8.1.4. France AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Organization Size

15.8.1.4.1. Small and Medium Organizations

15.8.1.4.2. Large Organizations

15.8.1.5. France AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area

15.8.1.5.1. Cardiovascular Disease

15.8.1.5.2. Metabolic Disease

15.8.1.5.3. Neurodegenerative Diseases

15.8.1.5.4. Dermatological Diseases

15.8.1.5.5. Infectious Diseases

15.8.1.5.6. Oncology

15.8.1.5.7. Others

15.8.1.6. France AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By End Users

15.8.1.6.1. Pharmaceutical Companies

15.8.1.6.2. Research Centers and Laboratories

15.8.1.6.3. Clinicians and Drug Developers

15.8.1.6.4. Others

15.8.2. The UK

15.8.2.1. The UK AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Drug Type

15.8.2.1.1. Small Molecule

15.8.2.1.2. Large Molecule

15.8.2.2. The UK AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Technology

15.8.2.2.1. Deep Learning

15.8.2.2.2. Machine Learning

15.8.2.2.3. Others

15.8.2.3. The UK AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Application

15.8.2.3.1. Target Identification and Validation

15.8.2.3.2. Drugs Design and Redesign

15.8.2.3.3. Preclinical Testing

15.8.2.3.4. Others

15.8.2.4. The UK AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Organization Size

15.8.2.4.1. Small and Medium Organizations

15.8.2.4.2. Large Organizations

15.8.2.5. The UK AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area

15.8.2.5.1. Cardiovascular Disease

15.8.2.5.2. Metabolic Disease

15.8.2.5.3. Neurodegenerative Diseases

15.8.2.5.4. Dermatological Diseases

15.8.2.5.5. Infectious Diseases

15.8.2.5.6. Oncology

15.8.2.5.7. Others

15.8.2.6. The UK AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By End Users

15.8.2.6.1. Pharmaceutical Companies

15.8.2.6.2. Research Centers and Laboratories

15.8.2.6.3. Clinicians and Drug Developers

15.8.2.6.4. Others

15.8.3. Spain

15.8.3.1. Spain AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Drug Type

15.8.3.1.1. Small Molecule

15.8.3.1.2. Large Molecule

15.8.3.2. Spain AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Technology

15.8.3.2.1. Deep Learning

15.8.3.2.2. Machine Learning

15.8.3.2.3. Others

15.8.3.3. Spain AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Application

15.8.3.3.1. Target Identification and Validation

15.8.3.3.2. Drugs Design and Redesign

15.8.3.3.3. Preclinical Testing

15.8.3.3.4. Others

15.8.3.4. Spain AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Organization Size

15.8.3.4.1. Small and Medium Organizations

15.8.3.4.2. Large Organizations

15.8.3.5. Spain AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area

15.8.3.5.1. Cardiovascular Disease

15.8.3.5.2. Metabolic Disease

15.8.3.5.3. Neurodegenerative Diseases

15.8.3.5.4. Dermatological Diseases

15.8.3.5.5. Infectious Diseases

15.8.3.5.6. Oncology

15.8.3.5.7. Others

15.8.3.6. Spain AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By End Users

15.8.3.6.1. Pharmaceutical Companies

15.8.3.6.2. Research Centers and Laboratories

15.8.3.6.3. Clinicians and Drug Developers

15.8.3.6.4. Others

15.8.4. Germany

15.8.4.1. Germany AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Drug Type

15.8.4.1.1. Small Molecule

15.8.4.1.2. Large Molecule

15.8.4.2. Germany AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Technology

15.8.4.2.1. Deep Learning

15.8.4.2.2. Machine Learning

15.8.4.2.3. Others

15.8.4.3. Germany AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Application

15.8.4.3.1. Target Identification and Validation

15.8.4.3.2. Drugs Design and Redesign

15.8.4.3.3. Preclinical Testing

15.8.4.3.4. Others

15.8.4.4. Germany AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Organization Size

15.8.4.4.1. Small and Medium Organizations

15.8.4.4.2. Large Organizations

15.8.4.5. Germany AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area

15.8.4.5.1. Cardiovascular Disease

15.8.4.5.2. Metabolic Disease

15.8.4.5.3. Neurodegenerative Diseases

15.8.4.5.4. Dermatological Diseases

15.8.4.5.5. Infectious Diseases

15.8.4.5.6. Oncology

15.8.4.5.7. Others

15.8.4.6. Germany AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By End Users

15.8.4.6.1. Pharmaceutical Companies

15.8.4.6.2. Research Centers and Laboratories

15.8.4.6.3. Clinicians and Drug Developers

15.8.4.6.4. Others

15.8.5. Italy

15.8.5.1. Italy AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Drug Type

15.8.5.1.1. Small Molecule

15.8.5.1.2. Large Molecule

15.8.5.2. Italy AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Technology

15.8.5.2.1. Deep Learning

15.8.5.2.2. Machine Learning

15.8.5.2.3. Others

15.8.5.3. Italy AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Application

15.8.5.3.1. Target Identification and Validation

15.8.5.3.2. Drugs Design and Redesign

15.8.5.3.3. Preclinical Testing

15.8.5.3.4. Others

15.8.5.4. Italy AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Organization Size

15.8.5.4.1. Small and Medium Organizations

15.8.5.4.2. Large Organizations

15.8.5.5. Italy AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area

15.8.5.5.1. Cardiovascular Disease

15.8.5.5.2. Metabolic Disease

15.8.5.5.3. Neurodegenerative Diseases

15.8.5.5.4. Dermatological Diseases

15.8.5.5.5. Infectious Diseases

15.8.5.5.6. Oncology

15.8.5.5.7. Others

15.8.5.6. Italy AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By End Users

15.8.5.6.1. Pharmaceutical Companies

15.8.5.6.2. Research Centers and Laboratories

15.8.5.6.3. Clinicians and Drug Developers

15.8.5.6.4. Others

15.8.6. Nordic Countries

15.8.6.1. Nordic Countries AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Drug Type

15.8.6.1.1. Small Molecule

15.8.6.1.2. Large Molecule

15.8.6.2. Nordic Countries AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Technology

15.8.6.2.1. Deep Learning

15.8.6.2.2. Machine Learning

15.8.6.2.3. Others

15.8.6.3. Nordic Countries AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Application

15.8.6.3.1. Target Identification and Validation

15.8.6.3.2. Drugs Design and Redesign

15.8.6.3.3. Preclinical Testing

15.8.6.3.4. Others

15.8.6.4. Nordic Countries AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Organization Size

15.8.6.4.1. Small and Medium Organizations

15.8.6.4.2. Large Organizations

15.8.6.5. Nordic Countries AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area

15.8.6.5.1. Cardiovascular Disease

15.8.6.5.2. Metabolic Disease

15.8.6.5.3. Neurodegenerative Diseases

15.8.6.5.4. Dermatological Diseases

15.8.6.5.5. Infectious Diseases

15.8.6.5.6. Oncology

15.8.6.5.7. Others

15.8.6.6. Nordic Countries AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By End Users

15.8.6.6.1. Pharmaceutical Companies

15.8.6.6.2. Research Centers and Laboratories

15.8.6.6.3. Clinicians and Drug Developers

15.8.6.6.4. Others

15.8.6.7. Nordic Countries AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Country

15.8.6.7.1. Denmark

15.8.6.7.2. Finland

15.8.6.7.3. Iceland

15.8.6.7.4. Sweden

15.8.6.7.5. Norway

15.8.7. Benelux Union

15.8.7.1. Benelux Union AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Drug Type

15.8.7.1.1. Small Molecule

15.8.7.1.2. Large Molecule

15.8.7.2. Benelux Union AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Technology

15.8.7.2.1. Deep Learning

15.8.7.2.2. Machine Learning

15.8.7.2.3. Others

15.8.7.3. Benelux Union AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Application

15.8.7.3.1. Target Identification and Validation

15.8.7.3.2. Drugs Design and Redesign

15.8.7.3.3. Preclinical Testing

15.8.7.3.4. Others

15.8.7.4. Benelux Union AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Organization Size

15.8.7.4.1. Small and Medium Organizations

15.8.7.4.2. Large Organizations

15.8.7.5. Benelux Union AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area

15.8.7.5.1. Cardiovascular Disease

15.8.7.5.2. Metabolic Disease

15.8.7.5.3. Neurodegenerative Diseases

15.8.7.5.4. Dermatological Diseases

15.8.7.5.5. Infectious Diseases

15.8.7.5.6. Oncology

15.8.7.5.7. Others

15.8.7.6. Benelux Union AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By End Users

15.8.7.6.1. Pharmaceutical Companies

15.8.7.6.2. Research Centers and Laboratories

15.8.7.6.3. Clinicians and Drug Developers

15.8.7.6.4. Others

15.8.7.7. Benelux Union AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Country

15.8.7.7.1. Belgium

15.8.7.7.2. The Netherlands

15.8.7.7.3. Luxembourg

15.8.8. Rest of Europe

15.8.8.1. Rest of Europe AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Drug Type

15.8.8.1.1. Small Molecule

15.8.8.1.2. Large Molecule

15.8.8.2. Rest of Europe AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Technology

15.8.8.2.1. Deep Learning

15.8.8.2.2. Machine Learning

15.8.8.2.3. Others

15.8.8.3. Rest of Europe AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Application

15.8.8.3.1. Target Identification and Validation

15.8.8.3.2. Drugs Design and Redesign

15.8.8.3.3. Preclinical Testing

15.8.8.3.4. Others

15.8.8.4. Rest of Europe AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Organization Size

15.8.8.4.1. Small and Medium Organizations

15.8.8.4.2. Large Organizations

15.8.8.5. Rest of Europe AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area

15.8.8.5.1. Cardiovascular Disease

15.8.8.5.2. Metabolic Disease

15.8.8.5.3. Neurodegenerative Diseases

15.8.8.5.4. Dermatological Diseases

15.8.8.5.5. Infectious Diseases

15.8.8.5.6. Oncology

15.8.8.5.7. Others

15.8.8.6. Rest of Europe AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By End Users

15.8.8.6.1. Pharmaceutical Companies

15.8.8.6.2. Research Centers and Laboratories

15.8.8.6.3. Clinicians and Drug Developers

15.8.8.6.4. Others

15.9. Key Segment for Channeling Investments

15.9.1. By Country

15.9.2. By Drug Type

15.9.3. By Technology

15.9.4. By Application

15.9.5. By Organization Size

15.9.6. By Therapeutic Area

15.9.7. By End Users

16. Asia Pacific AI in Drug Discovery Market Analysis and Forecasts, 2020 - 2028

16.1. Overview

16.1.1. Asia Pacific AI in Drug Discovery Market Revenue (US$ Mn)

16.2. Asia Pacific AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Drug Type

16.2.1. Small Molecule

16.2.2. Large Molecule

16.3. Asia Pacific AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Technology

16.3.1. Deep Learning

16.3.2. Machine Learning

16.3.3. Others

16.4. Asia Pacific AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Application

16.4.1. Target Identification and Validation

16.4.2. Drugs Design and Redesign

16.4.3. Preclinical Testing

16.4.4. Others

16.5. Asia Pacific AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Organization Size

16.5.1. Small and Medium Organizations

16.5.2. Large Organizations

16.6. Asia Pacific AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area

16.6.1. Cardiovascular Disease

16.6.2. Metabolic Disease

16.6.3. Neurodegenerative Diseases

16.6.4. Dermatological Diseases

16.6.5. Infectious Diseases

16.6.6. Oncology

16.6.7. Others

16.7. Asia Pacific AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By End Users

16.7.1. Pharmaceutical Companies

16.7.2. Research Centers and Laboratories

16.7.3. Clinicians and Drug Developers

16.7.4. Others

16.8. Asia Pacific AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Country

16.8.1. China

16.8.1.1. China AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Drug Type

16.8.1.1.1. Small Molecule

16.8.1.1.2. Large Molecule

16.8.1.2. China AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Technology

16.8.1.2.1. Deep Learning

16.8.1.2.2. Machine Learning

16.8.1.2.3. Others

16.8.1.3. China AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Application

16.8.1.3.1. Target Identification and Validation

16.8.1.3.2. Drugs Design and Redesign

16.8.1.3.3. Preclinical Testing

16.8.1.3.4. Others

16.8.1.4. China AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Organization Size

16.8.1.4.1. Small and Medium Organizations

16.8.1.4.2. Large Organizations

16.8.1.5. China AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area

16.8.1.5.1. Cardiovascular Disease

16.8.1.5.2. Metabolic Disease

16.8.1.5.3. Neurodegenerative Diseases

16.8.1.5.4. Dermatological Diseases

16.8.1.5.5. Infectious Diseases

16.8.1.5.6. Oncology

16.8.1.5.7. Others

16.8.1.6. China AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By End Users

16.8.1.6.1. Pharmaceutical Companies

16.8.1.6.2. Research Centers and Laboratories

16.8.1.6.3. Clinicians and Drug Developers

16.8.1.6.4. Others

16.8.2. Japan

16.8.2.1. Japan AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Drug Type

16.8.2.1.1. Small Molecule

16.8.2.1.2. Large Molecule

16.8.2.2. Japan AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Technology

16.8.2.2.1. Deep Learning

16.8.2.2.2. Machine Learning

16.8.2.2.3. Others

16.8.2.3. Japan AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Application

16.8.2.3.1. Target Identification and Validation

16.8.2.3.2. Drugs Design and Redesign

16.8.2.3.3. Preclinical Testing

16.8.2.3.4. Others

16.8.2.4. Japan AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Organization Size

16.8.2.4.1. Small and Medium Organizations

16.8.2.4.2. Large Organizations

16.8.2.5. Japan AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area

16.8.2.5.1. Cardiovascular Disease

16.8.2.5.2. Metabolic Disease

16.8.2.5.3. Neurodegenerative Diseases

16.8.2.5.4. Dermatological Diseases

16.8.2.5.5. Infectious Diseases

16.8.2.5.6. Oncology

16.8.2.5.7. Others

16.8.2.6. Japan AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By End Users

16.8.2.6.1. Pharmaceutical Companies

16.8.2.6.2. Research Centers and Laboratories

16.8.2.6.3. Clinicians and Drug Developers

16.8.2.6.4. Others

16.8.3. India

16.8.3.1. India AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Drug Type

16.8.3.1.1. Small Molecule

16.8.3.1.2. Large Molecule

16.8.3.2. India AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Technology

16.8.3.2.1. Deep Learning

16.8.3.2.2. Machine Learning

16.8.3.2.3. Others

16.8.3.3. India AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Application

16.8.3.3.1. Target Identification and Validation

16.8.3.3.2. Drugs Design and Redesign

16.8.3.3.3. Preclinical Testing

16.8.3.3.4. Others

16.8.3.4. India AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Organization Size

16.8.3.4.1. Small and Medium Organizations

16.8.3.4.2. Large Organizations

16.8.3.5. India AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area

16.8.3.5.1. Cardiovascular Disease

16.8.3.5.2. Metabolic Disease

16.8.3.5.3. Neurodegenerative Diseases

16.8.3.5.4. Dermatological Diseases

16.8.3.5.5. Infectious Diseases

16.8.3.5.6. Oncology

16.8.3.5.7. Others

16.8.3.6. India AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By End Users

16.8.3.6.1. Pharmaceutical Companies

16.8.3.6.2. Research Centers and Laboratories

16.8.3.6.3. Clinicians and Drug Developers

16.8.3.6.4. Others

16.8.4. New Zealand

16.8.4.1. New Zealand AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Drug Type

16.8.4.1.1. Small Molecule

16.8.4.1.2. Large Molecule

16.8.4.2. New Zealand AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Technology

16.8.4.2.1. Deep Learning

16.8.4.2.2. Machine Learning

16.8.4.2.3. Others

16.8.4.3. New Zealand AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Application

16.8.4.3.1. Target Identification and Validation

16.8.4.3.2. Drugs Design and Redesign

16.8.4.3.3. Preclinical Testing

16.8.4.3.4. Others

16.8.4.4. New Zealand AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Organization Size

16.8.4.4.1. Small and Medium Organizations

16.8.4.4.2. Large Organizations

16.8.4.5. New Zealand AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area

16.8.4.5.1. Cardiovascular Disease

16.8.4.5.2. Metabolic Disease

16.8.4.5.3. Neurodegenerative Diseases

16.8.4.5.4. Dermatological Diseases

16.8.4.5.5. Infectious Diseases

16.8.4.5.6. Oncology

16.8.4.5.7. Others

16.8.4.6. New Zealand AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By End Users

16.8.4.6.1. Pharmaceutical Companies

16.8.4.6.2. Research Centers and Laboratories

16.8.4.6.3. Clinicians and Drug Developers

16.8.4.6.4. Others

16.8.5. Australia

16.8.5.1. Australia AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Drug Type

16.8.5.1.1. Small Molecule

16.8.5.1.2. Large Molecule

16.8.5.2. Australia AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Technology

16.8.5.2.1. Deep Learning

16.8.5.2.2. Machine Learning

16.8.5.2.3. Others

16.8.5.3. Australia AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Application

16.8.5.3.1. Target Identification and Validation

16.8.5.3.2. Drugs Design and Redesign

16.8.5.3.3. Preclinical Testing

16.8.5.3.4. Others

16.8.5.4. Australia AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Organization Size

16.8.5.4.1. Small and Medium Organizations

16.8.5.4.2. Large Organizations

16.8.5.5. Australia AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area

16.8.5.5.1. Cardiovascular Disease

16.8.5.5.2. Metabolic Disease

16.8.5.5.3. Neurodegenerative Diseases

16.8.5.5.4. Dermatological Diseases

16.8.5.5.5. Infectious Diseases

16.8.5.5.6. Oncology

16.8.5.5.7. Others

16.8.5.6. Australia AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By End Users

16.8.5.6.1. Pharmaceutical Companies

16.8.5.6.2. Research Centers and Laboratories

16.8.5.6.3. Clinicians and Drug Developers

16.8.5.6.4. Others

16.8.6. South Korea

16.8.6.1. South Korea AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Drug Type

16.8.6.1.1. Small Molecule

16.8.6.1.2. Large Molecule

16.8.6.2. South Korea AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Technology

16.8.6.2.1. Deep Learning

16.8.6.2.2. Machine Learning

16.8.6.2.3. Others

16.8.6.3. South Korea AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Application

16.8.6.3.1. Target Identification and Validation

16.8.6.3.2. Drugs Design and Redesign

16.8.6.3.3. Preclinical Testing

16.8.6.3.4. Others

16.8.6.4. South Korea AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Organization Size

16.8.6.4.1. Small and Medium Organizations

16.8.6.4.2. Large Organizations

16.8.6.5. South Korea AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area

16.8.6.5.1. Cardiovascular Disease

16.8.6.5.2. Metabolic Disease

16.8.6.5.3. Neurodegenerative Diseases

16.8.6.5.4. Dermatological Diseases

16.8.6.5.5. Infectious Diseases

16.8.6.5.6. Oncology

16.8.6.5.7. Others

16.8.6.6. South Korea AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By End Users

16.8.6.6.1. Pharmaceutical Companies

16.8.6.6.2. Research Centers and Laboratories

16.8.6.6.3. Clinicians and Drug Developers

16.8.6.6.4. Others

16.8.7. Southeast Asia

16.8.7.1. Southeast Asia AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Drug Type

16.8.7.1.1. Small Molecule

16.8.7.1.2. Large Molecule

16.8.7.2. Southeast Asia AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Technology

16.8.7.2.1. Deep Learning

16.8.7.2.2. Machine Learning

16.8.7.2.3. Others

16.8.7.3. Southeast Asia AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Application

16.8.7.3.1. Target Identification and Validation

16.8.7.3.2. Drugs Design and Redesign

16.8.7.3.3. Preclinical Testing

16.8.7.3.4. Others

16.8.7.4. Southeast Asia AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Organization Size

16.8.7.4.1. Small and Medium Organizations

16.8.7.4.2. Large Organizations

16.8.7.5. Southeast Asia AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area

16.8.7.5.1. Cardiovascular Disease

16.8.7.5.2. Metabolic Disease

16.8.7.5.3. Neurodegenerative Diseases

16.8.7.5.4. Dermatological Diseases

16.8.7.5.5. Infectious Diseases

16.8.7.5.6. Oncology

16.8.7.5.7. Others

16.8.7.6. Southeast Asia AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By End Users

16.8.7.6.1. Pharmaceutical Companies

16.8.7.6.2. Research Centers and Laboratories

16.8.7.6.3. Clinicians and Drug Developers

16.8.7.6.4. Others

16.8.7.7. Southeast Asia AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Country

16.8.7.7.1. Indonesia

16.8.7.7.2. Thailand

16.8.7.7.3. Malaysia

16.8.7.7.4. Singapore

16.8.7.7.5. Rest of Southeast Asia

16.8.8. Rest of Asia Pacific

16.8.8.1. Rest of Asia Pacific AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Drug Type

16.8.8.1.1. Small Molecule

16.8.8.1.2. Large Molecule

16.8.8.2. Rest of Asia Pacific AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Technology

16.8.8.2.1. Deep Learning

16.8.8.2.2. Machine Learning

16.8.8.2.3. Others

16.8.8.3. Rest of Asia Pacific AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Application

16.8.8.3.1. Target Identification and Validation

16.8.8.3.2. Drugs Design and Redesign

16.8.8.3.3. Preclinical Testing

16.8.8.3.4. Others

16.8.8.4. Rest of Asia Pacific AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Organization Size

16.8.8.4.1. Small and Medium Organizations

16.8.8.4.2. Large Organizations

16.8.8.5. Rest of Asia Pacific AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area

16.8.8.5.1. Cardiovascular Disease

16.8.8.5.2. Metabolic Disease

16.8.8.5.3. Neurodegenerative Diseases

16.8.8.5.4. Dermatological Diseases

16.8.8.5.5. Infectious Diseases

16.8.8.5.6. Oncology

16.8.8.5.7. Others

16.8.8.6. Rest of Asia Pacific AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By End Users

16.8.8.6.1. Pharmaceutical Companies

16.8.8.6.2. Research Centers and Laboratories

16.8.8.6.3. Clinicians and Drug Developers

16.8.8.6.4. Others

16.9. Key Segment for Channeling Investments

16.9.1. By Country

16.9.2. By Drug Type

16.9.3. By Technology

16.9.4. By Application

16.9.5. By Organization Size

16.9.6. By Therapeutic Area

16.9.7. By End Users

17. Middle East and Africa AI in Drug Discovery Market Analysis and Forecasts, 2020 - 2028

17.1. Overview

17.1.1. Middle East and Africa AI in Drug Discovery Market Revenue (US$ Mn)

17.2. Middle East and Africa AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Drug Type

17.2.1. Small Molecule

17.2.2. Large Molecule

17.3. Middle East and Africa AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Technology

17.3.1. Deep Learning

17.3.2. Machine Learning

17.3.3. Others

17.4. Middle East and Africa AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Application

17.4.1. Target Identification and Validation

17.4.2. Drugs Design and Redesign

17.4.3. Preclinical Testing

17.4.4. Others

17.5. Middle East and Africa AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Organization Size

17.5.1. Small and Medium Organizations

17.5.2. Large Organizations

17.6. Middle East and Africa AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area

17.6.1. Cardiovascular Disease

17.6.2. Metabolic Disease

17.6.3. Neurodegenerative Diseases

17.6.4. Dermatological Diseases

17.6.5. Infectious Diseases

17.6.6. Oncology

17.6.7. Others

17.7. Middle East and Africa AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By End Users

17.7.1. Pharmaceutical Companies

17.7.2. Research Centers and Laboratories

17.7.3. Clinicians and Drug Developers

17.7.4. Others

17.8. Middle East and Africa AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Country

17.8.1. Saudi Arabia

17.8.1.1. Saudi Arabia AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Drug Type

17.8.1.1.1. Small Molecule

17.8.1.1.2. Large Molecule

17.8.1.2. Saudi Arabia AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Technology

17.8.1.2.1. Deep Learning

17.8.1.2.2. Machine Learning

17.8.1.2.3. Others

17.8.1.3. Saudi Arabia AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Application

17.8.1.3.1. Target Identification and Validation

17.8.1.3.2. Drugs Design and Redesign

17.8.1.3.3. Preclinical Testing

17.8.1.3.4. Others

17.8.1.4. Saudi Arabia AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Organization Size

17.8.1.4.1. Small and Medium Organizations

17.8.1.4.2. Large Organizations

17.8.1.5. Saudi Arabia AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area

17.8.1.5.1. Cardiovascular Disease

17.8.1.5.2. Metabolic Disease

17.8.1.5.3. Neurodegenerative Diseases

17.8.1.5.4. Dermatological Diseases

17.8.1.5.5. Infectious Diseases

17.8.1.5.6. Oncology

17.8.1.5.7. Others

17.8.1.6. Saudi Arabia AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By End Users

17.8.1.6.1. Pharmaceutical Companies

17.8.1.6.2. Research Centers and Laboratories

17.8.1.6.3. Clinicians and Drug Developers

17.8.1.6.4. Others

17.8.2. UAE

17.8.2.1. UAE AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Drug Type

17.8.2.1.1. Small Molecule

17.8.2.1.2. Large Molecule

17.8.2.2. UAE AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Technology

17.8.2.2.1. Deep Learning

17.8.2.2.2. Machine Learning

17.8.2.2.3. Others

17.8.2.3. UAE AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Application

17.8.2.3.1. Target Identification and Validation

17.8.2.3.2. Drugs Design and Redesign

17.8.2.3.3. Preclinical Testing

17.8.2.3.4. Others

17.8.2.4. UAE AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Organization Size

17.8.2.4.1. Small and Medium Organizations

17.8.2.4.2. Large Organizations

17.8.2.5. UAE AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area

17.8.2.5.1. Cardiovascular Disease

17.8.2.5.2. Metabolic Disease

17.8.2.5.3. Neurodegenerative Diseases

17.8.2.5.4. Dermatological Diseases

17.8.2.5.5. Infectious Diseases

17.8.2.5.6. Oncology

17.8.2.5.7. Others

17.8.2.6. UAE AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By End Users

17.8.2.6.1. Pharmaceutical Companies

17.8.2.6.2. Research Centers and Laboratories

17.8.2.6.3. Clinicians and Drug Developers

17.8.2.6.4. Others

17.8.3. Egypt

17.8.3.1. Egypt AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Drug Type

17.8.3.1.1. Small Molecule

17.8.3.1.2. Large Molecule

17.8.3.2. Egypt AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Technology

17.8.3.2.1. Deep Learning

17.8.3.2.2. Machine Learning

17.8.3.2.3. Others

17.8.3.3. Egypt AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Application

17.8.3.3.1. Target Identification and Validation

17.8.3.3.2. Drugs Design and Redesign

17.8.3.3.3. Preclinical Testing

17.8.3.3.4. Others

17.8.3.4. Egypt AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Organization Size

17.8.3.4.1. Small and Medium Organizations

17.8.3.4.2. Large Organizations

17.8.3.5. Egypt AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area

17.8.3.5.1. Cardiovascular Disease

17.8.3.5.2. Metabolic Disease

17.8.3.5.3. Neurodegenerative Diseases

17.8.3.5.4. Dermatological Diseases

17.8.3.5.5. Infectious Diseases

17.8.3.5.6. Oncology

17.8.3.5.7. Others

17.8.3.6. Egypt AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By End Users

17.8.3.6.1. Pharmaceutical Companies

17.8.3.6.2. Research Centers and Laboratories

17.8.3.6.3. Clinicians and Drug Developers

17.8.3.6.4. Others

17.8.4. Kuwait

17.8.4.1. Kuwait AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Drug Type

17.8.4.1.1. Small Molecule

17.8.4.1.2. Large Molecule

17.8.4.2. Kuwait AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Technology

17.8.4.2.1. Deep Learning

17.8.4.2.2. Machine Learning

17.8.4.2.3. Others

17.8.4.3. Kuwait AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Application

17.8.4.3.1. Target Identification and Validation

17.8.4.3.2. Drugs Design and Redesign

17.8.4.3.3. Preclinical Testing

17.8.4.3.4. Others

17.8.4.4. Kuwait AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Organization Size

17.8.4.4.1. Small and Medium Organizations

17.8.4.4.2. Large Organizations

17.8.4.5. Kuwait AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area

17.8.4.5.1. Cardiovascular Disease

17.8.4.5.2. Metabolic Disease

17.8.4.5.3. Neurodegenerative Diseases

17.8.4.5.4. Dermatological Diseases

17.8.4.5.5. Infectious Diseases

17.8.4.5.6. Oncology

17.8.4.5.7. Others

17.8.4.6. Kuwait AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By End Users

17.8.4.6.1. Pharmaceutical Companies

17.8.4.6.2. Research Centers and Laboratories

17.8.4.6.3. Clinicians and Drug Developers

17.8.4.6.4. Others

17.8.5. South Africa

17.8.5.1. South Africa AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Drug Type

17.8.5.1.1. Small Molecule

17.8.5.1.2. Large Molecule

17.8.5.2. South Africa AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Technology

17.8.5.2.1. Deep Learning

17.8.5.2.2. Machine Learning

17.8.5.2.3. Others

17.8.5.3. South Africa AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Application

17.8.5.3.1. Target Identification and Validation

17.8.5.3.2. Drugs Design and Redesign

17.8.5.3.3. Preclinical Testing

17.8.5.3.4. Others

17.8.5.4. South Africa AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Organization Size

17.8.5.4.1. Small and Medium Organizations

17.8.5.4.2. Large Organizations

17.8.5.5. South Africa AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area

17.8.5.5.1. Cardiovascular Disease

17.8.5.5.2. Metabolic Disease

17.8.5.5.3. Neurodegenerative Diseases

17.8.5.5.4. Dermatological Diseases

17.8.5.5.5. Infectious Diseases

17.8.5.5.6. Oncology

17.8.5.5.7. Others

17.8.5.6. South Africa AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By End Users

17.8.5.6.1. Pharmaceutical Companies

17.8.5.6.2. Research Centers and Laboratories

17.8.5.6.3. Clinicians and Drug Developers

17.8.5.6.4. Others

17.8.6. Rest of Middle East & Africa

17.8.6.1. Rest of Middle East & Africa AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Drug Type

17.8.6.1.1. Small Molecule

17.8.6.1.2. Large Molecule

17.8.6.2. Rest of Middle East & Africa AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Technology

17.8.6.2.1. Deep Learning

17.8.6.2.2. Machine Learning

17.8.6.2.3. Others

17.8.6.3. Rest of Middle East & Africa AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Application

17.8.6.3.1. Target Identification and Validation

17.8.6.3.2. Drugs Design and Redesign

17.8.6.3.3. Preclinical Testing

17.8.6.3.4. Others

17.8.6.4. Rest of Middle East & Africa AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Organization Size

17.8.6.4.1. Small and Medium Organizations

17.8.6.4.2. Large Organizations

17.8.6.5. Rest of Middle East & Africa AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area

17.8.6.5.1. Cardiovascular Disease

17.8.6.5.2. Metabolic Disease

17.8.6.5.3. Neurodegenerative Diseases

17.8.6.5.4. Dermatological Diseases

17.8.6.5.5. Infectious Diseases

17.8.6.5.6. Oncology

17.8.6.5.7. Others

17.8.6.6. Rest of Middle East & Africa AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By End Users

17.8.6.6.1. Pharmaceutical Companies

17.8.6.6.2. Research Centers and Laboratories

17.8.6.6.3. Clinicians and Drug Developers

17.8.6.6.4. Others

17.9. Key Segment for Channeling Investments

17.9.1. By Country

17.9.2. By Drug Type

17.9.3. By Technology

17.9.4. By Application

17.9.5. By Organization Size

17.9.6. By Therapeutic Area

17.9.7. By End Users

18. Latin America AI in Drug Discovery Market Analysis and Forecasts, 2020 - 2028

18.1. Overview

18.1.1. Latin America AI in Drug Discovery Market Revenue (US$ Mn)

18.2. Latin America AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Drug Type

18.2.1. Small Molecule

18.2.2. Large Molecule

18.3. Latin America AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Technology

18.3.1. Deep Learning

18.3.2. Machine Learning

18.3.3. Others

18.4. Latin America AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Application

18.4.1. Target Identification and Validation

18.4.2. Drugs Design and Redesign

18.4.3. Preclinical Testing

18.4.4. Others

18.5. Latin America AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Organization Size

18.5.1. Small and Medium Organizations

18.5.2. Large Organizations

18.6. Latin America AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area

18.6.1. Cardiovascular Disease

18.6.2. Metabolic Disease

18.6.3. Neurodegenerative Diseases

18.6.4. Dermatological Diseases

18.6.5. Infectious Diseases

18.6.6. Oncology

18.6.7. Others

18.7. Latin America AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By End Users

18.7.1. Pharmaceutical Companies

18.7.2. Research Centers and Laboratories

18.7.3. Clinicians and Drug Developers

18.7.4. Others

18.8. Latin America AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Country

18.8.1. Brazil

18.8.1.1. Brazil AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Drug Type

18.8.1.1.1. Small Molecule

18.8.1.1.2. Large Molecule

18.8.1.2. Brazil AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Technology

18.8.1.2.1. Deep Learning

18.8.1.2.2. Machine Learning

18.8.1.2.3. Others

18.8.1.3. Brazil AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Application

18.8.1.3.1. Target Identification and Validation

18.8.1.3.2. Drugs Design and Redesign

18.8.1.3.3. Preclinical Testing

18.8.1.3.4. Others

18.8.1.4. Brazil AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Organization Size

18.8.1.4.1. Small and Medium Organizations

18.8.1.4.2. Large Organizations

18.8.1.5. Brazil AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area

18.8.1.5.1. Cardiovascular Disease

18.8.1.5.2. Metabolic Disease

18.8.1.5.3. Neurodegenerative Diseases

18.8.1.5.4. Dermatological Diseases

18.8.1.5.5. Infectious Diseases

18.8.1.5.6. Oncology

18.8.1.5.7. Others

18.8.1.6. Brazil AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By End Users

18.8.1.6.1. Pharmaceutical Companies

18.8.1.6.2. Research Centers and Laboratories

18.8.1.6.3. Clinicians and Drug Developers

18.8.1.6.4. Others

18.8.2. Argentina

18.8.2.1. Argentina AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Drug Type

18.8.2.1.1. Small Molecule

18.8.2.1.2. Large Molecule

18.8.2.2. Argentina AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Technology

18.8.2.2.1. Deep Learning

18.8.2.2.2. Machine Learning

18.8.2.2.3. Others

18.8.2.3. Argentina AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Application

18.8.2.3.1. Target Identification and Validation

18.8.2.3.2. Drugs Design and Redesign

18.8.2.3.3. Preclinical Testing

18.8.2.3.4. Others

18.8.2.4. Argentina AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Organization Size

18.8.2.4.1. Small and Medium Organizations

18.8.2.4.2. Large Organizations

18.8.2.5. Argentina AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area

18.8.2.5.1. Cardiovascular Disease

18.8.2.5.2. Metabolic Disease

18.8.2.5.3. Neurodegenerative Diseases

18.8.2.5.4. Dermatological Diseases

18.8.2.5.5. Infectious Diseases

18.8.2.5.6. Oncology

18.8.2.5.7. Others

18.8.2.6. Argentina AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By End Users

18.8.2.6.1. Pharmaceutical Companies

18.8.2.6.2. Research Centers and Laboratories

18.8.2.6.3. Clinicians and Drug Developers

18.8.2.6.4. Others

18.8.3. Rest of Latin America

18.8.3.1. Rest of Latin America AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Drug Type

18.8.3.1.1. Small Molecule

18.8.3.1.2. Large Molecule

18.8.3.2. Rest of Latin America AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Technology

18.8.3.2.1. Deep Learning

18.8.3.2.2. Machine Learning

18.8.3.2.3. Others

18.8.3.3. Rest of Latin America AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Application

18.8.3.3.1. Target Identification and Validation

18.8.3.3.2. Drugs Design and Redesign

18.8.3.3.3. Preclinical Testing

18.8.3.3.4. Others

18.8.3.4. Rest of Latin America AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Organization Size

18.8.3.4.1. Small and Medium Organizations

18.8.3.4.2. Large Organizations

18.8.3.5. Rest of Latin America AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area

18.8.3.5.1. Cardiovascular Disease

18.8.3.5.2. Metabolic Disease

18.8.3.5.3. Neurodegenerative Diseases

18.8.3.5.4. Dermatological Diseases

18.8.3.5.5. Infectious Diseases

18.8.3.5.6. Oncology

18.8.3.5.7. Others

18.8.3.6. Rest of Latin America AI in Drug Discovery Market Revenue (US$ Mn) and Forecasts, By End Users

18.8.3.6.1. Pharmaceutical Companies

18.8.3.6.2. Research Centers and Laboratories

18.8.3.6.3. Clinicians and Drug Developers

18.8.3.6.4. Others

18.9. Key Segment for Channeling Investments

18.9.1. By Country

18.9.2. By Drug Type

18.9.3. By Technology

18.9.4. By Application

18.9.5. By Organization Size

18.9.6. By Therapeutic Area

18.9.7. By End Users

19. Competitive Benchmarking

19.1. Market Share Analysis, 2019

19.2. Global Presence and Growth Strategies

19.2.1. Mergers and Acquisitions

19.2.2. Product Launches

19.2.3. Investments Trends

19.2.4. R&D Initiatives

20. Player Profiles

20.1. Atomwise, Inc

20.1.1. Company Details

20.1.2. Company Overview

20.1.3. Product Offerings

20.1.4. Key Developments

20.1.5. Financial Analysis

20.1.6. SWOT Analysis

20.1.7. Business Strategies

20.2. BenevolentAI Ltd

20.2.1. Company Details

20.2.2. Company Overview

20.2.3. Product Offerings

20.2.4. Key Developments

20.2.5. Financial Analysis

20.2.6. SWOT Analysis

20.2.7. Business Strategies

20.3. BERG LLC

20.3.1. Company Details

20.3.2. Company Overview

20.3.3. Product Offerings

20.3.4. Key Developments

20.3.5. Financial Analysis

20.3.6. SWOT Analysis

20.3.7. Business Strategies

20.4. BIOAGE

20.4.1. Company Details

20.4.2. Company Overview

20.4.3. Product Offerings

20.4.4. Key Developments

20.4.5. Financial Analysis

20.4.6. SWOT Analysis

20.4.7. Business Strategies

20.5. Cloud Pharmaceuticals, Inc.

20.5.1. Company Details

20.5.2. Company Overview

20.5.3. Product Offerings

20.5.4. Key Developments

20.5.5. Financial Analysis

20.5.6. SWOT Analysis

20.5.7. Business Strategies

20.6. Cyclica

20.6.1. Company Details

20.6.2. Company Overview

20.6.3. Product Offerings

20.6.4. Key Developments

20.6.5. Financial Analysis

20.6.6. SWOT Analysis

20.6.7. Business Strategies

20.7. DEEP GENOMICS

20.7.1. Company Details

20.7.2. Company Overview

20.7.3. Product Offerings

20.7.4. Key Developments

20.7.5. Financial Analysis

20.7.6. SWOT Analysis

20.7.7. Business Strategies

20.8. Envisagenics

20.8.1. Company Details

20.8.2. Company Overview

20.8.3. Product Offerings

20.8.4. Key Developments

20.8.5. Financial Analysis

20.8.6. SWOT Analysis

20.8.7. Business Strategies

20.9. EVAXION BIOTECH A/S

20.9.1. Company Details

20.9.2. Company Overview

20.9.3. Product Offerings

20.9.4. Key Developments

20.9.5. Financial Analysis

20.9.6. SWOT Analysis

20.9.7. Business Strategies

20.10. Exscientia

20.10.1. Company Details

20.10.2. Company Overview

20.10.3. Product Offerings

20.10.4. Key Developments

20.10.5. Financial Analysis

20.10.6. SWOT Analysis

20.10.7. Business Strategies

20.11. Google LLC

20.11.1. Company Details

20.11.2. Company Overview

20.11.3. Product Offerings

20.11.4. Key Developments

20.11.5. Financial Analysis

20.11.6. SWOT Analysis

20.11.7. Business Strategies

20.12. HACARUS INC

20.12.1. Company Details

20.12.2. Company Overview

20.12.3. Product Offerings

20.12.4. Key Developments

20.12.5. Financial Analysis

20.12.6. SWOT Analysis

20.12.7. Business Strategies

20.13. IBM Corp

20.13.1. Company Details

20.13.2. Company Overview

20.13.3. Product Offerings

20.13.4. Key Developments

20.13.5. Financial Analysis

20.13.6. SWOT Analysis

20.13.7. Business Strategies

20.14. Insilico Medicine

20.14.1. Company Details

20.14.2. Company Overview

20.14.3. Product Offerings

20.14.4. Key Developments

20.14.5. Financial Analysis

20.14.6. SWOT Analysis

20.14.7. Business Strategies

20.15. Microsoft

20.15.1. Company Details

20.15.2. Company Overview

20.15.3. Product Offerings

20.15.4. Key Developments

20.15.5. Financial Analysis

20.15.6. SWOT Analysis

20.15.7. Business Strategies

20.16. NuMedii, Inc.

20.16.1. Company Details

20.16.2. Company Overview

20.16.3. Product Offerings

20.16.4. Key Developments

20.16.5. Financial Analysis

20.16.6. SWOT Analysis

20.16.7. Business Strategies

20.17. OWKIN, INC.

20.17.1. Company Details

20.17.2. Company Overview

20.17.3. Product Offerings

20.17.4. Key Developments

20.17.5. Financial Analysis

20.17.6. SWOT Analysis

20.17.7. Business Strategies

20.18. twoXAR, Incorporated

20.18.1. Company Details

20.18.2. Company Overview

20.18.3. Product Offerings

20.18.4. Key Developments

20.18.5. Financial Analysis

20.18.6. SWOT Analysis

20.18.7. Business Strategies

20.19. VERGE genomics

20.19.1. Company Details

20.19.2. Company Overview

20.19.3. Product Offerings

20.19.4. Key Developments

20.19.5. Financial Analysis

20.19.6. SWOT Analysis

20.19.7. Business Strategies

20.20. XtalPi Inc.

20.20.1. Company Details

20.20.2. Company Overview

20.20.3. Product Offerings

20.20.4. Key Developments

20.20.5. Financial Analysis

20.20.6. SWOT Analysis

20.20.7. Business Strategies

20.21. Other Industry Participants

21. Key Findings

Note: This ToC is tentative and can be changed according to the research study conducted during the course of report completion.

**Exclusive for Multi-User and Enterprise User.

At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.

Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.

Prominent participants in our primary research process include:

Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
Research and development participants, distributors/suppliers and subject matter experts

Secondary Research includes data extracted from paid data sources:

Reuters
Factiva
Bloomberg
One Source
Hoovers

Research Methodology

Key Inclusions

Request A Sample

Ask for Discount

Enquiry Before Buying

Request For Customization

Purchase Options

Single users $3300

Multi users $7300

Global users $7300

Buy Now

Reach to us

Call us on

+91-74002-42424

Drop us an email at

sales@absolutemarketsinsights.com